A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international
study assessing the activity of durvalumab and chemotherapy administered prior to surgery
compared with placebo and chemotherapy administered prior to surgery in terms of pathological
complete response.